Market Overview

AstraZeneca Begins Phase III Study of FASLODEX Injection in Patients with Hormone Receptor-Positive Advanced Breast Cancer


(NYSE: AZN) today announced the start of a Phase III study (FALCON), a
global clinical trial which will involve 450 postmenopausal patients
with hormone receptor-positive locally advanced or metastatic breast
cancer who have not previously been treated with any hormonal therapy.
The Phase III study is designed to evaluate the efficacy and
tolerability of fulvestrant 500 mg compared to anastrozole 1 mg in this
patient population.

Fulvestrant 500 mg is currently indicated for the treatment of hormone
receptor-positive metastatic breast cancer in postmenopausal women with
disease progression following antiestrogen therapy. FASLODEX is
contraindicated in patients with known hypersensitivity to the drug or
to any of its components. Hypersensitivity

See full press release

Posted-In: Earnings News Guidance Management Global


Related Articles (AZN)

View Comments and Join the Discussion!